ERBB2
Universal Cellular Machinery · Phosphorylation & Kinase Signaling Cascades
Is an ERBB2 variant the same as a HER2-positive tumor result?
ERBB2 encodes HER2, a receptor that partners with related growth-factor receptors. Tumor testing for HER2 expression or amplification measures specific cancer features and is not interchangeable with an inherited variant report.
- Common Gene Name
- erb-b2 receptor tyrosine kinase 2
- NCBI Gene ID
- 2064
- Chromosome
- 17
Clinical Evidence Status
Tumor or drug-label biomarker context
These labels describe available evidence about a gene. They do not classify your variant or recommend a treatment.
Answer Sources
Explore supporting evidence (34 records)
| Condition or drug | Evidence | Grade / status | Context | Source |
|---|---|---|---|---|
| Abemaciclib (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Ado-Trastuzumab Emtansine | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Alpelisib (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Capecitabine (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Capivasertib (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Elacestrant (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Eribulin (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Everolimus (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Fam-Trastuzumab Deruxtecan-nxki (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Fulvestrant (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Ixabepilone (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Lapatinib (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Margetuximab-cmkb (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Neratinib (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Nivolumab (6) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Olaparib (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Palbociclib (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Pembrolizumab (7) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Pertuzumab (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Ribociclib (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Sacituzumab Govitecan-hziy (4) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Talazoparib (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Tipiracil and Trifluridine (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Trastuzumab (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Tucatinib (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Datopotamab Deruxtecan-dlnk (3) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Imlunestrant (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Inavolisib (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Sevabertinib (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Tislelizumab-jsgr (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Zanidatamab-hrii | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Zolbetuximab-clzb (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Zongertinib | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
| Vepdegestrant (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
Source snapshot: 2026-09-09. Consumer text updated: 2026-09-10. Source dates describe the cited records, not a new clinical review.
← Back to Universal Cellular Machinery